Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome.

//Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome.

Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome.

Encantados de compartir un interesante debate, coordinado con Zogenix, sobre la metodología de Análisis de Decisión Multicriterio (MCDA) como una nueva herramienta para el empoderamiento de los pacientes con Síndrome de Dravet. Desde la perspectiva de los pacientes y de sus cuidadores, el MCDA se consideró como una herramienta útil que permite valorar enfermedades, y sobre todo dar voz a los pacientes.

Delighted to share an interesting debate, coordinated with Zogenix, about the Multiple Criteria Decision Analysis (MCDA) methodology as a new tool to empowerment of patients suffering from Dravet Syndrome. From patients’ perspective and their caregivers, MCDA was considered a useful way to assess a disease and raise patients’ voice.

https://www.diariofarma.com/2020/12/20/los-pacientes-con-sindrome-de-dravet-creen-prioritario-poner-de-manifiesto-la-gravedad-de-la-enfermedad

 

2020-12-23T12:14:39+00:00December 23rd, 2020|News & Events|